How India Exports Erlotinib to the World

In the United States, erlotinib is marketed under the brand name Tarceva. The FDA has approved multiple Abbreviated New Drug Applications (ANDAs) for generic versions of erlotinib, facilitating market entry for Indian exporters. The presence of 94 active Indian exporters underscores the competitive landscape and the importance of adhering to FDA regulations to maintain market access.

The European Medicines Agency (EMA) granted marketing authorization for Tarceva (erlotinib) on September 19, 2005, for the treatment of NSCLC. Generic versions, such as Erlotinib Accord, have also been evaluated; however, Accord Healthcare S.L.U. withdrew its application on May 11, 2020, due to inadequate bioequivalence data. (ema.europa.eu) Compliance with EU Good Manufacturing Practice (GMP) standards is mandatory for market entry, necessitating rigorous quality assurance measures from Indian exporters.

Erlotinib is included in the 21st edition of the WHO Model List of Essential Medicines, highlighting its significance in global cancer treatment protocols. While not listed in the WHO Prequalification Programme, erlotinib must conform to international pharmacopoeia standards, including those of the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Adherence to these standards ensures the quality and efficacy of erlotinib in international markets.

In India, erlotinib is classified under Schedule H of the Drugs and Cosmetics Rules, 1945, indicating it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not imposed a ceiling price on erlotinib, allowing market-driven pricing. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC), ensuring compliance with national regulations and monitoring of pharmaceutical exports.

The primary patents for erlotinib have expired, leading to increased generic competition. This has enabled numerous Indian pharmaceutical companies to manufacture and export generic versions, contributing to the $2.7 million USD export value recorded between 2022 and 2026.

- July 2025: The FDA granted orphan drug designation to erlotinib for the treatment of pachyonychia congenita, expanding its therapeutic applications.

- September 2024: The European Commission withdrew the marketing authorization for Gefitinib Mylan at the request of the marketing authorization holder, Mylan Pharmaceuticals Limited, due to commercial reasons. (ema.europa.eu)

- May 2020: Accord Healthcare S.L.U. withdrew its application for marketing authorization of Erlotinib Accord in the EU, citing inadequate bioequivalence data. (ema.europa.eu)

These developments underscore the dynamic regulatory environment surrounding erlotinib, necessitating continuous monitoring and compliance by Indian exporters to maintain and expand their market presence.

Erlotinib's Active Pharmaceutical Ingredient (API) is predominantly manufactured in India, a leading global producer of generic pharmaceuticals. However, India's API production heavily relies on importing Key Starting Materials (KSMs) and intermediates from China, which supplies approximately 70–80% of the global KSMs and 60–70% of intermediates. This dependency exposes the supply chain to risks associated with geopolitical tensions, trade disputes, and regulatory changes in China.

Recent disruptions have underscored these vulnerabilities. For instance, in March 2026, the closure of the Strait of Hormuz due to escalating Middle East conflicts disrupted the supply of raw materials to Asia's petrochemical industry, leading to force majeure declarations and production cutbacks. Such events highlight the fragility of supply chains dependent on specific regions for critical inputs.

Our proprietary trade data indicates that the top five Indian exporters of Erlotinib account for 69.7% of total exports, with NATCO PHARMA LIMITED leading at a 20.4% share. This high supplier concentration poses a significant risk; any operational or regulatory issues affecting these key players could disrupt the global supply of Erlotinib.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to bolster domestic API and KSM manufacturing capacity. This initiative seeks to reduce reliance on imports and enhance supply chain resilience. (pharmanow.live) However, the effectiveness of the PLI scheme in diversifying the supplier base and reducing single-source dependency remains to be fully realized.

Geopolitical tensions have significantly impacted global shipping routes critical to pharmaceutical supply chains. In February 2026, the closure of the Strait of Hormuz following U.S. and Israeli attacks on Iran disrupted the supply of raw materials to Asia's petrochemical industry, leading to production cutbacks. Additionally, in June 2025, the threat to commercial shipping in the Strait of Hormuz, Red Sea, and Gulf of Aden increased due to escalating conflicts, raising concerns about the security of these vital maritime corridors.

These disruptions have led to increased freight costs, longer transit times, and potential delays in the delivery of pharmaceutical products, including Erlotinib. Furthermore, the U.S. Food and Drug Administration (FDA) has been actively monitoring supply chain issues, emphasizing the need for robust strategies to mitigate such risks.

• Diversify Supplier Base: Encourage the development of alternative suppliers for Erlotinib and its raw materials to reduce dependency on a limited number of exporters.

• Enhance Domestic Production: Support initiatives like the PLI scheme to strengthen domestic manufacturing capabilities for APIs and KSMs, decreasing reliance on imports.

• Strengthen Supply Chain Monitoring: Implement advanced tracking systems to monitor geopolitical developments and shipping routes, enabling proactive responses to potential disruptions.

• Develop Contingency Plans: Establish comprehensive contingency strategies, including alternative transportation routes and stockpiling essential materials, to maintain supply continuity during crises.

• Engage in International Collaboration: Foster partnerships with international regulatory bodies and industry stakeholders to share information and coordinate responses to global supply chain challenges.

RISK_LEVEL: HIGH